Larry Allen Wheeler

This inventor holds 76 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Ocular Implants (CPC class A61K). Top assignees: Allergan, Inc., Allergan Sales, Inc., Johns Hopkins University. Active years: 1988-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Larry Allen Wheeler. Retrieved from https://idiyas.com/inventor/larry-allen-wheeler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 76 (Patent Applications = 14)

% Patents Active = 65.8

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 4.2

ph-index = 20

Forward Citations = 1,085(Granted Patents)

Forward Citations (Not Self Cited) = 1,011(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Johns Hopkins University

University of California

patents

7. 2 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1988-2019

Loading Chart...

Areas of Expertise:

Intraocular Implants

Retinal Diseases

Sustained Release

Ocular Vasculopathies

Pain Management

Alpha Adrenergic Agonists

Neurological Disorders

Imidazole Compounds

Selective Antagonists

Methods for Treating

Vision Improvement

Polypeptide Treatment

76 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10201641 - Sustained release intraocular implants and methods for treating ocular vasculopathies (2019-02-12),

2. 9561234 - Methods for treating diseases of the retina (2017-02-07),

3. 9161938 - Sustained release intraocular implants and methods for treating ocular vasculopathies (2015-10-20),

4. 9144543 - Sustained release intraocular implants and methods for preventing retinal dysfunction (2015-09-29),

5. 9018202 - Methods for treating diseases of the retina (2015-04-28),

6. 8609144 - Sustained release intraocular implants and methods for preventing retinal dysfunction (2013-12-17),

7. 8580292 - Sustained release intraocular implants and methods for treating ocular vasculopathies (2013-11-12),

8. 8506986 - Sustained release intraocular implants and methods for treating ocular vasculopathies (2013-08-13),

9. 8491912 - Methods of treating ocular and other diseases with Syn-134R polypeptide (2013-07-23),

10. 8455492 - Methods for treating retinal diseases (2013-06-04),

11. 8425929 - Sustained release intraocular implants and methods for preventing retinal dysfunction (2013-04-23),

12. 8293741 - Intraocular implants and methods for improving vision (2012-10-23),

13. 8293210 - Sustained release intraocular implants and methods for preventing retinal dysfunction (2012-10-23),

14. 8178571 - [object Object] (2012-05-15),

15. 8153645 - Treating pain using selective antagonists of persistent sodium current (2012-04-10),

Certainly! Here is a sample article for inventor Larry Allen Wheeler:

Title: The Innovative Mind of Larry Allen Wheeler: Revolutionizing Ophthalmic Treatments

Introduction:

Larry Allen Wheeler, a prolific inventor based in Irvine, CA, has left an indelible mark on the field of ophthalmology with his groundbreaking patents and contributions. With an impressive portfolio of 76 patents to his name, Wheeler's work continues to shape the landscape of ocular healthcare.

Latest Patents:

Wheeler's latest patents showcase his commitment to developing novel solutions for treating ocular vasculopathies and retinal disorders. His work on sustained release intraocular implants incorporating alpha-2 adrenergic receptor agonists demonstrates his dedication to innovative approaches in ophthalmic care.

Career Highlights:

Throughout his career, Wheeler has been associated with leading companies such as Allergan, Inc., and Allergan Sales, Inc., where he has honed his expertise in the field of ophthalmic research and development. His relentless pursuit of excellence has led to the successful implementation of numerous patents in the realm of ocular treatments.

Collaborations:

Wheeler has had the privilege of collaborating with esteemed professionals in the industry, including Michael E Garst and James A Burke. These fruitful collaborations have not only enriched Wheeler's work but have also contributed to the advancement of ophthalmic healthcare as a whole.

Conclusion:

In conclusion, Larry Allen Wheeler stands as a testament to the power of innovation and dedication in the field of ophthalmology. His pioneering work in developing advanced treatments for ocular conditions underscores his commitment to improving the lives of patients worldwide. Wheeler's legacy as an inventor continues to inspire future generations in the pursuit of excellence in ocular healthcare.

Profile summary based on public USPTO records.